BRIEF — Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis
Oct 12 (Reuters) — Syndax Pharmaceuticals, Inc.: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis Syndax Pharmaceuticals - Will Not Pursue Further Development Of Axatilimab In Ipf Syndax Pharmaceuticals - Axatilimab Well Tolerated With No New Safety Signals In M